NCT01068756View on ClinicalTrials.gov

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days

DRUG

Rifampin

Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days

Trial Locations (1)

78744

Ppd Development, Austin

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY